PTHrP Analog Composition for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current osteoporosis treatments face limitations due to unwanted side-effects such as hypercalcemia and increased bone resorption, restricting dosage ranges and reducing their beneficial effects.
Innovation Solution
A storage-stable composition of parathyroid hormone-related protein (PTHrP) is developed, specifically [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2, which can be administered in higher doses without increasing side-effects, maintaining stability at room temperature for extended periods and eliminating the need for chemical stabilizers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher dosages of PTHrP are administered to increase beneficial effects on bone mass, then therapeutic effectiveness is improved, but unwanted side-effects such as hypercalcemia and increased bone resorption increase
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of PTHrP to create analogs with altered properties. Specifically, substitutions at positions 22 and 25 (e.g., Glu22,25) and other positions create variants that maintain bone-forming activity while reducing calcium-mobilizing side effects. This chemical parameter modification allows higher dosages to be administered therapeutically without proportionally increasing harmful effects.
Solution Approach 2:
The invention applies local quality by making specific localized changes to the PTHrP molecule at particular amino acid positions (22, 25, and others) while leaving the rest of the structure intact. These localized substitutions create regions of different functionality: the N-terminal region maintains bone-stimulating activity while the modified regions reduce hypercalcemia induction, allowing differentiated local effects within the same molecule.
2Ease of operation
If PTHrP composition is stored at room temperature for extended periods to improve convenience of administration, then ease of operation is improved, but storage stability deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying physical-chemical parameters of the PTHrP analogs through amino acid substitutions that enhance conformational stability and resistance to degradation. These structural parameter changes enable the composition to maintain stability at higher temperatures (room temperature) whereas native PTHrP would require refrigeration, thus improving ease of operation without sacrificing stability.
3Stability of the object's composition
If chemical stabilizers are added to maintain storage stability, then stability of the object's composition is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The invention applies self-service by engineering the PTHrP analogs themselves to possess inherent stability properties through their modified amino acid structures. The analogs self-stabilize through their conformational properties and resistance to proteolytic degradation, eliminating the need for external chemical stabilizers. This self-service approach simplifies the formulation and reduces manufacturing complexity while maintaining stability.
Data Source
AI summary
The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.